Q/C Technologies, Inc. (QCLS) - Total Liabilities
Based on the latest financial reports, Q/C Technologies, Inc. (QCLS) has total liabilities worth $14.60 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore QCLS strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Q/C Technologies, Inc. - Total Liabilities Trend (2020–2025)
This chart illustrates how Q/C Technologies, Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see QCLS current and non-current assets.
Q/C Technologies, Inc. Competitors by Total Liabilities
The table below lists competitors of Q/C Technologies, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Deveron UAS Corp
V:FARM
|
Canada | CA$70.05 Million |
|
Blackrock Smaller Companies Trust PLC
LSE:BRSC
|
UK | GBX77.48 Million |
|
Intertainment AG
XETRA:ITN
|
Germany | €11.77 Million |
|
Starhedge SA
WAR:SHG
|
Poland | zł8.79 Million |
|
AKTIENBRAU.KAUFBEUR
MU:ABK
|
Germany | €5.77 Million |
|
Meihua International Medical Technologies Co. Ltd.
NASDAQ:MHUAF
|
USA | $18.25 Million |
|
GR BUSSINES SO
F:INW
|
Germany | €118.59K |
|
Treasure Global Inc.
NASDAQ:TGL
|
USA | $5.97 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Q/C Technologies, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Q/C Technologies, Inc. balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Q/C Technologies, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Q/C Technologies, Inc. (2020–2025)
The table below shows the annual total liabilities of Q/C Technologies, Inc. from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $19.41 Million | +189.71% |
| 2024-12-31 | $6.70 Million | +31.69% |
| 2023-12-31 | $5.09 Million | +78.87% |
| 2022-12-31 | $2.84 Million | +144.04% |
| 2021-12-31 | $1.17 Million | -80.35% |
| 2020-12-31 | $5.93 Million | -- |
About Q/C Technologies, Inc.
Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company. It operates through Pharmaceuticals and Computing Technology segments. The company develops Isomyosamine, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including sarcopenia, frailty, adverse effects of drugs used to treat diabetes and obesity, rheumatoid arthritis, … Read more